Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Peter R. Galle, Alejandro Forner, Josep M. Llovet, et al.
Journal of Hepatology (2018) Vol. 69, Iss. 1, pp. 182-236
Closed Access | Times Cited: 10108

Showing 26-50 of 10108 citing articles:

NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Dominik Pfister, Nicolás Gonzalo Núñez, Roser Pinyol, et al.
Nature (2021) Vol. 592, Iss. 7854, pp. 450-456
Open Access | Times Cited: 938
Advances in immunotherapy for hepatocellular carcinoma
Bruno Sangro, Pablo Sarobe, Sandra Hervás‐Stubbs, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 8, pp. 525-543
Open Access | Times Cited: 938
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
Bruno Sangro, Carlos Gómez-Martín, Manuel de la Mata, et al.
Journal of Hepatology (2013) Vol. 59, Iss. 1, pp. 81-88
Closed Access | Times Cited: 908
Alcoholic liver disease
Helmut K. Seitz, Ramón Bataller, Helena Cortez‐Pinto, et al.
Nature Reviews Disease Primers (2018) Vol. 4, Iss. 1
Closed Access | Times Cited: 903
Epidemiology and surveillance for hepatocellular carcinoma: New trends
Amit G. Singal, Pietro Lampertico, Pierre Nahon
Journal of Hepatology (2020) Vol. 72, Iss. 2, pp. 250-261
Open Access | Times Cited: 880
Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients
Victoria Chernyak, Kathryn J. Fowler, Aya Kamaya, et al.
Radiology (2018) Vol. 289, Iss. 3, pp. 816-830
Open Access | Times Cited: 876
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
Ghassan K. Abou‐Alfa, George Lau, Masatoshi Kudo, et al.
NEJM Evidence (2022) Vol. 1, Iss. 8
Open Access | Times Cited: 873
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
Thomas Yau, Joong‐Won Park, Richard S. Finn, et al.
The Lancet Oncology (2021) Vol. 23, Iss. 1, pp. 77-90
Closed Access | Times Cited: 840
EASL Clinical Practice Guidelines: Management of alcohol-related liver disease
Mark Thursz, Antoni Gual, C. Lackner, et al.
Journal of Hepatology (2018) Vol. 69, Iss. 1, pp. 154-181
Open Access | Times Cited: 762
Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma
Ying Jiang, Aihua Sun, Yang Zhao, et al.
Nature (2019) Vol. 567, Iss. 7747, pp. 257-261
Closed Access | Times Cited: 756
Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009
Zobair M. Younossi, Munkhzul Otgonsuren, Linda Henry, et al.
Hepatology (2015) Vol. 62, Iss. 6, pp. 1723-1730
Closed Access | Times Cited: 741
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
Philip J. Johnson, Shukui Qin, Joong‐Won Park, et al.
Journal of Clinical Oncology (2013) Vol. 31, Iss. 28, pp. 3517-3524
Open Access | Times Cited: 738
Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma
Josep M. Llovet, Thierry de Baère, Laura Kulik, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 5, pp. 293-313
Closed Access | Times Cited: 694
Tumour evolution in hepatocellular carcinoma
Amanda J. Craig, Johann von Felden, Teresa García‐Lezana, et al.
Nature Reviews Gastroenterology & Hepatology (2019) Vol. 17, Iss. 3, pp. 139-152
Closed Access | Times Cited: 681
β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma
Marina Ruiz de Galarreta, Erin Bresnahan, Pedro Molina-Sánchez, et al.
Cancer Discovery (2019) Vol. 9, Iss. 8, pp. 1124-1141
Open Access | Times Cited: 670
Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)
Jian Zhou, Hui‐Chuan Sun, Zheng Wang, et al.
Liver Cancer (2020) Vol. 9, Iss. 6, pp. 682-720
Open Access | Times Cited: 651
NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis
Chi Ma, Aparna H. Kesarwala, Tobias Eggert, et al.
Nature (2016) Vol. 531, Iss. 7593, pp. 253-257
Open Access | Times Cited: 642
Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma
Yun‐Fan Sun, Liang Wu, Yu Zhong, et al.
Cell (2020) Vol. 184, Iss. 2, pp. 404-421.e16
Open Access | Times Cited: 625
The diagnosis and treatment of hepatocellular carcinoma
Justin Hartke, Matthew S. Johnson, Marwan Ghabril
Seminars in Diagnostic Pathology (2016) Vol. 34, Iss. 2, pp. 153-159
Closed Access | Times Cited: 597
Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma
Riad Salem, Andrew C. Gordon, S. Mouli, et al.
Gastroenterology (2016) Vol. 151, Iss. 6, pp. 1155-1163.e2
Open Access | Times Cited: 585
Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
Josep M. Llovet, Thomas Decaens, Jean‐Luc Raoul, et al.
Journal of Clinical Oncology (2013) Vol. 31, Iss. 28, pp. 3509-3516
Open Access | Times Cited: 583
JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan
Masatoshi Kudo, Osamu Matsui, Namiki Izumi, et al.
Liver Cancer (2014) Vol. 3, Iss. 3-4, pp. 458-468
Open Access | Times Cited: 582
Advances in targeted therapies for hepatocellular carcinoma in the genomic era
Josep M. Llovet, Augusto Villanueva, Anja Lachenmayer, et al.
Nature Reviews Clinical Oncology (2015) Vol. 12, Iss. 7, pp. 408-424
Closed Access | Times Cited: 572
Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial
Masatoshi Kudo, Kazuomi Ueshima, Masafumi Ikeda, et al.
Gut (2019) Vol. 69, Iss. 8, pp. 1492-1501
Open Access | Times Cited: 568
TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease
Yang‐Lin Liu, Helen L. Reeves, Alastair D. Burt, et al.
Nature Communications (2014) Vol. 5, Iss. 1
Open Access | Times Cited: 566

Scroll to top